Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
Top Cited Papers
Open Access
- 1 September 2001
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 12 (9), 1247-1254
- https://doi.org/10.1023/a:1012281104865
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patientsCancer Chemotherapy and Pharmacology, 2000
- Optimizing Chemotherapy for Patients with Advanced Breast CancerOncology, 1999
- Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast CancerJournal of Clinical Oncology, 1999
- Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.Journal of Clinical Oncology, 1998
- Treatment of Breast CancerNew England Journal of Medicine, 1998
- Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissueEuropean Journal Of Cancer, 1998
- Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer.British Journal of Cancer, 1998
- Tumor Selective Delivery of 5-Fluorouracil by Capecitabine, a New Oral Fluoropyrimidine Carbamate, in Human Cancer XenograftsBiochemical Pharmacology, 1998
- A study of quality of life in cancer patients receiving palliative chemotherapySocial Science & Medicine, 1992
- “Classical” CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer: An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)European Journal of Cancer and Clinical Oncology, 1991